TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Nona Biosciences and Lycia Therapeutics Establish Collaborative Partnership

Monday, December 04, 2023

Nona Biosciences, a global leader in technology innovation and antibody discovery solutions, recently announced a collaboration agreement with Lycia Therapeutics, a company specializing in extracellular protein degradation. Lycia uses its proprietary lysosomal targeting chimeras (LYTACs) platform to discover therapeutics that degrade extracellular and membrane-bound proteins associated with challenging-to-treat diseases. In this collaboration, Lycia will use Nona's Harbour Mice® HCAb fully human antibody transgenic mice platform to identify antibodies for its LYTAC protein degrader therapeutics.

Jingsong Wang, M.D., Ph.D., Chairman of Nona Biosciences, expressed enthusiasm about the collaboration, stating, "We are pleased to collaborate with Lycia Therapeutics, expanding our service capabilities to include extracellular protein degradation. We believe that Lycia's use of our antibody discovery expertise will expedite the development of novel protein degrader therapeutics."

Steve Staben, Ph.D., Chief Scientific Officer of Lycia Therapeutics, highlighted the unique potential of LYTACs in addressing challenging extracellular disease targets. Staben said, "Our LYTACs can uniquely address extracellular disease-driving targets that remain challenging for existing antibody and small molecule modalities. We look forward to leveraging Nona Biosciences' technology to enhance the discovery of novel therapeutics for currently underserved patient populations."

 

Source: prnewswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit